Corvus Pharmaceuticals, Inc. Equity Securities, FV-NI, Realized Gain (Loss)
Corvus Pharmaceuticals, Inc. (CRVS) reported Equity Securities, FV-NI, Realized Gain (Loss) of -$5.28 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2024-03-19
- Corvus Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2023-12-31 was -$1.40M.
- Corvus Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2023-09-30 was -$865.00K.
- Corvus Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2023-06-30 was -$1.28M.
- Corvus Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2023-03-31 was -$1.73M.
- Corvus Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2023 was -$5.28M.
- Corvus Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2022 was -$10.01M.
- Corvus Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2021 was -$4.83M.
- Corvus Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2020 was -$234.00K.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$2.27M derived: sum of 2 quarters · filed 2024-03-19 | -$3.55M derived: sum of 3 quarters · filed 2024-03-19 | -$5.28M 10-K · filed 2024-03-19 |
| 2023-09-30 | -$865.00K 10-Q · filed 2023-11-07 | -$2.15M derived: sum of 2 quarters · filed 2023-11-07 | -$3.88M 10-Q · filed 2023-11-07 | -$8.52M derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-06-30 | -$1.28M 10-Q · filed 2023-08-08 | -$3.02M 10-Q · filed 2023-08-08 | -$7.65M derived: sum of 3 quarters · filed 2024-03-19 | -$10.38M derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-03-31 | -$1.73M 10-Q · filed 2023-05-08 | -$6.37M derived: sum of 2 quarters · filed 2024-03-19 | -$9.10M derived: sum of 3 quarters · filed 2024-03-19 | -$10.70M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | -$4.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$7.37M derived: sum of 2 quarters · filed 2024-03-19 | -$8.96M derived: sum of 3 quarters · filed 2024-03-19 | -$10.01M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$2.73M 10-Q · filed 2023-11-07 | -$4.33M derived: sum of 2 quarters · filed 2023-11-07 | -$5.37M 10-Q · filed 2023-11-07 | -$7.93M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | -$1.60M 10-Q · filed 2023-08-08 | -$2.64M 10-Q · filed 2023-08-08 | -$5.20M derived: sum of 3 quarters · filed 2024-03-19 | -$6.91M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | -$1.04M 10-Q · filed 2023-05-08 | -$3.60M derived: sum of 2 quarters · filed 2024-03-19 | -$5.31M derived: sum of 3 quarters · filed 2024-03-19 | -$5.77M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | -$2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$4.27M derived: sum of 2 quarters · filed 2024-03-19 | -$4.73M derived: sum of 3 quarters · filed 2024-03-19 | -$4.83M 10-K · filed 2024-03-19 |
| 2021-09-30 | -$1.71M 10-Q · filed 2022-11-03 | -$2.17M derived: sum of 2 quarters · filed 2022-11-03 | -$2.27M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$463.00K 10-Q · filed 2022-08-08 | -$563.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$100.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$234.00K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |